Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.
Article
CAS
PubMed
Google Scholar
Henriksen A, et al. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019;78:17–30.
Article
CAS
PubMed
Google Scholar
Wolfgang CL, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63(5):318–48.
Article
PubMed
PubMed Central
Google Scholar
Bliss LA, et al. Outcomes in operative management of pancreatic cancer. J Surg Oncol. 2014;110(5):592–8.
Article
PubMed
Google Scholar
Darvin P, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11.
Article
PubMed
Google Scholar
Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ribas A, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18.
Article
CAS
PubMed
PubMed Central
Google Scholar
Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.
Article
CAS
PubMed
Google Scholar
Rizvi NA, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Garon EB, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.
Article
PubMed
Google Scholar
Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
Article
CAS
PubMed
Google Scholar
Motzer RJ, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7.
Article
CAS
PubMed
Google Scholar
Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2015;7(6):365–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Powles T, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.
Article
CAS
PubMed
Google Scholar
Powles T, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3(9):e172411.
Article
PubMed
PubMed Central
Google Scholar
Royal RE, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sakaguchi S, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1950). 1995;155(3):1151–64.
CAS
Google Scholar
Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295–307.
Article
CAS
PubMed
Google Scholar
Oleinika K, et al. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol. 2013;171(1):36–45.
Article
CAS
PubMed
Google Scholar
Taylor A, et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology. 2006;117(4):433–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sakaguchi S, et al. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–87.
Article
CAS
PubMed
Google Scholar
Chinen T, et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol. 2016;17(11):1322–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1950). 1999;163(10):5211–8.
CAS
Google Scholar
Shitara K, Nishikawa H. Regulatory T cells: a potential target in cancer immunotherapy: regulatory T cells in cancer immunity. Ann N Y Acad Sci. 2018;1417(1):104–15.
Article
CAS
PubMed
Google Scholar
Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28(8):401–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bauer CA, et al. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J Clin Investig. 2014;124(6):2425–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Walunas TL, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity (Cambridge, Mass). 1994;1(5):405.
CAS
Google Scholar
Alegre M-L, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4(12):1206–12.
Article
PubMed
Google Scholar
Budhu S, et al. Blockade of surface-bound TGF-beta on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal. 2017;10(494):eaak9702.
Article
PubMed
PubMed Central
Google Scholar
Jang J-E, et al. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep (Cambridge). 2017;20(3):558–71.
Article
CAS
Google Scholar
Kim J-H, Kim BS, Lee S-K. Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy. Immune Netw. 2020;20(1):e4–e4.
Article
PubMed
PubMed Central
Google Scholar
De Simone M, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity (Cambridge, Mass). 2016;45(5):1135–47.
Google Scholar
Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96(1):21–33.
Article
CAS
PubMed
Google Scholar
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–68.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pergamo M, Miller G. Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Ther. 2017;24(3):100–5.
Article
CAS
PubMed
Google Scholar
Kusmartsev S, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181(1):346–53.
Article
CAS
PubMed
Google Scholar
Fulton SA, et al. Inhibition of major histocompatibility complex II expression and antigen processing in murine alveolar macrophages by mycobacterium bovis BCG and the 19-kilodalton mycobacterial lipoprotein. Infect Immun. 2004;72(4):2101–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74.
Article
PubMed
PubMed Central
Google Scholar
Stromnes IM, et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014;63(11):1769–81.
Article
CAS
PubMed
Google Scholar
Huang BO, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced t regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (Chicago, Ill). 2006;66(2):1123–31.
Article
CAS
Google Scholar
Pinton L, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget. 2016;7(2):1168–84.
Article
PubMed
Google Scholar
Yang S, Liu Q, Liao Q. Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming. Front Cell Dev Biol. 2020;8:607209.
Article
PubMed
Google Scholar
Lankadasari MB, et al. TAMing pancreatic cancer: combat with a double edged sword. Mol Cancer. 2019;18(1):48.
Article
PubMed
PubMed Central
Google Scholar
Grimshaw MJ, Balkwill FR. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation–a potential mechanism. Eur J Immunol. 2001;31(2):480–9.
Article
CAS
PubMed
Google Scholar
Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35(5):585–600.
Article
CAS
PubMed
Google Scholar
Caux C, et al. A milestone review on how macrophages affect tumor growth. Cancer Res (Chicago, Ill). 2016;76(22):6439–42.
Article
CAS
Google Scholar
Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Beavis PA, et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res. 2015;3(5):506–17.
Article
CAS
PubMed
Google Scholar
Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol. 2012;3:344.
Article
PubMed
PubMed Central
Google Scholar
Hamada S, et al. IL-6/STAT3 plays a regulatory role in the interaction between pancreatic stellate cells and cancer cells. Dig Dis Sci. 2016;61(6):1561–71.
Article
CAS
PubMed
Google Scholar
Tang D, et al. Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. Tumor Biol. 2015;36(7):5617–26.
Article
CAS
Google Scholar
Tang D, et al. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer. 2012;130(10):2337–48.
Article
CAS
PubMed
Google Scholar
Ene-Obong A, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013;145(5):1121–32.
Article
CAS
PubMed
Google Scholar
Li C, et al. Pancreatic stellate cells promote tumor progression by promoting an immunosuppressive microenvironment in murine models of pancreatic cancer. Pancreas. 2020;49(1):120–7.
Article
CAS
PubMed
Google Scholar
Ozdemir BC, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2015;28(6):831–3.
Article
CAS
PubMed
Google Scholar
Jonescheit H, et al. Influence of indoleamine-2,3-dioxygenase and its metabolite kynurenine on γδ T cell cytotoxicity against ductal pancreatic adenocarcinoma cells. Cells (Basel, Switzerland). 2020;9(5):1140.
CAS
Google Scholar
Fan JQ, et al. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer. 2020;19(1):32.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang CJ, et al. Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J Immunol. 2012;189(3):1118–22.
Article
CAS
PubMed
Google Scholar
Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 2015;4(5):661–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.
Article
CAS
PubMed
Google Scholar
Skelton RA, et al. Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. J Surg Oncol. 2017;116(1):55–62.
Article
CAS
PubMed
Google Scholar
Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4(5):336–47.
Article
CAS
PubMed
Google Scholar
Keir ME, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
Article
CAS
PubMed
Google Scholar
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–24.
Article
CAS
PubMed
Google Scholar
Zhu B, et al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene. 2018;37(36):4941–54.
Article
CAS
PubMed
Google Scholar
Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother (1997). 2007;30(3):251–60.
Article
CAS
Google Scholar
Latchman YE, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci PNAS. 2004;101(29):10691–6.
Article
CAS
PubMed
Google Scholar
Yokosuka T, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201–17.
Article
CAS
PubMed
PubMed Central
Google Scholar
Davoodzadeh Gholami M, et al. Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol. 2017;322:1–14.
Article
CAS
PubMed
Google Scholar
Feng M, et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Lett. 2017;407:57–65.
Article
CAS
PubMed
Google Scholar
Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
Article
CAS
PubMed
Google Scholar
Lu SW, et al. IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models. Nat Commun. 2020;11(1):4611.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tessier-Cloutier B, et al. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer. 2017;17(1):618.
Article
PubMed
PubMed Central
Google Scholar
Gao HL, et al. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: a meta-analysis. Hepatobiliary Pancreat Dis Int. 2018;17(2):95–100.
Article
PubMed
Google Scholar
Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol. 2011;344:269–78.
CAS
PubMed
PubMed Central
Google Scholar
Long L, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5–6):176–89.
Article
CAS
PubMed
PubMed Central
Google Scholar
Meyers JH, et al. The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med. 2005;11(8):362–9.
Article
CAS
PubMed
Google Scholar
Jones RB, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205(12):2763–79.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu C, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245–52.
Article
CAS
PubMed
Google Scholar
Huang YH, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386–90.
Article
CAS
PubMed
Google Scholar
Li G, Liang X, Lotze MT. HMGB1: the central cytokine for all lymphoid cells. Front Immunol. 2013;4:68–68.
Article
PubMed
PubMed Central
Google Scholar
Nakayama M, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113(16):3821–30.
Article
CAS
PubMed
Google Scholar
Monney L, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536–41.
Article
CAS
PubMed
Google Scholar
Saka D, et al. Mechanisms of T-cell exhaustion in pancreatic cancer. Cancers (Basel). 2020;12(8):2274.
Article
CAS
Google Scholar
Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57.
Article
CAS
PubMed
Google Scholar
Stanietsky N, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106(42):17858–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dougall WC, et al. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276(1):112–20.
Article
CAS
PubMed
Google Scholar
Qin S, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.
Article
PubMed
PubMed Central
Google Scholar
Ni L, Dong C. New checkpoints in cancer immunotherapy. Immunol Rev. 2017;276(1):52–65.
Article
CAS
PubMed
Google Scholar
Wang L, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208(3):577–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Blando J, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci PNAS. 2019;116(5):1692–7.
Article
CAS
PubMed
Google Scholar
Blando J, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019;116(5):1692–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chapoval AI, et al. B7–H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269–74.
Article
CAS
PubMed
Google Scholar
Prasad DVR, et al. Murine B7–H3 is a negative regulator of T cells. J Immunol (1950). 2004;173(4):2500–6.
Article
CAS
Google Scholar
Suh WK, et al. The B7 family member B7–H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4(9):899–906.
Article
CAS
PubMed
Google Scholar
Yang S, Wei W, Zhao Q. B7–H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16(11):1767–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34(11):556–63.
Article
CAS
PubMed
Google Scholar
Han P, et al. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol (1950). 2004;172(10):5931–9.
Article
CAS
Google Scholar
Owada T, et al. Activation-induced accumulation of B and T lymphocyte attenuator at the immunological synapse in CD4+ T cells. J Leukoc Biol. 2010;87(3):425–32.
Article
CAS
PubMed
Google Scholar
Russano M, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res. 2020;39(1):95.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hopkins AC, et al. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI Insight. 2018;3(13):e122092.
Article
PubMed Central
Google Scholar
Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer: barriers and breakthroughs. Ann Gastroenterol Surg. 2018;2(4):274–81.
Article
PubMed
PubMed Central
Google Scholar
Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Patnaik A, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–93.
Article
CAS
PubMed
Google Scholar
Eso Y, Seno H. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Ther Adv Gastroenterol. 2020;13:1756284820948773.
Article
CAS
Google Scholar
Kraman M, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330(6005):827–30.
Article
CAS
PubMed
Google Scholar
Steele CW, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 2016;29(6):832–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Peng M, et al. Apolipoprotein A-I mimetic peptide L-4F suppresses granulocytic-myeloid-derived suppressor cells in mouse pancreatic cancer. Front Pharmacol. 2020;11:576.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huang HL, et al. LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo. Sci Rep. 2016;6:27794.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu Y, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057–69.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu Y, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res (Chicago, Ill). 2014;74(18):5057–69.
Article
CAS
Google Scholar
Kumar V, et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 2017;32(5):654-668.e5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou W, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021;268:120546.
Article
CAS
PubMed
Google Scholar
Zamarin D, et al. Mogamulizumab in combination with durvalumab or tremelimumab in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2020;26(17):4531–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang K, et al. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. Cancer Lett. 2020;472:8–18.
Article
CAS
PubMed
Google Scholar
Zhang Y, et al. Heat shock protein-90 inhibition alters activation of pancreatic stellate cells and enhances the efficacy of PD-1 blockade in pancreatic cancer. Mol Cancer Ther. 2021;20(1):150–60.
Article
CAS
PubMed
Google Scholar
Sharma NS, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Investig. 2020;130(1):451–65.
Article
CAS
PubMed
Google Scholar
Feig C, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci PNAS. 2013;110(50):20212–7.
Article
CAS
PubMed
Google Scholar
Bockorny B, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878–85.
Article
CAS
PubMed
Google Scholar
Orozco CA, et al. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A. 2018;115(16):E3769–78.
Article
CAS
PubMed
PubMed Central
Google Scholar
Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 2020;21(3):e135–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zheng Y, et al. Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol. 2015;294(1):54–9.
Article
CAS
PubMed
Google Scholar
Eriksson E, et al. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med. 2016;14(1):282–282.
Article
PubMed
PubMed Central
Google Scholar
Vincent J, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–61.
Article
CAS
PubMed
Google Scholar
Nomi T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151–7.
Article
CAS
PubMed
Google Scholar
Ho TTB, et al. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. J Immunother Cancer. 2020;8(2):e001367.
Article
PubMed
PubMed Central
Google Scholar
Ma J, et al. Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunol Immunother. 2020;69(3):365–72.
Article
CAS
PubMed
Google Scholar
Kalyan A, et al. Ipilimumab and gemcitabine for advanced pancreas cancer: a phase Ib study. J Clin Oncol. 2016;34(15_suppl):e15747–e15747.
Article
Google Scholar
Weiss GJ, et al. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Investig New Drugs. 2018;36(1):96–102.
Article
CAS
Google Scholar
Reits EA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15(6):366–81.
Article
PubMed
PubMed Central
Google Scholar
Azad A, et al. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med. 2017;9(2):167–80.
Article
CAS
PubMed
Google Scholar
Liu M, et al. IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion. Mol Med Rep. 2020;21(1):445–53.
CAS
PubMed
Google Scholar
Agrawal V, Benjamin KT, Ko EC. Radiotherapy and immunotherapy combinations for lung cancer. Curr Oncol Rep. 2020;23(1):4.
Article
PubMed
Google Scholar
Vrankar M, Kern I, Stanic K. Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. Radiat Oncol. 2020;15(1):247.
Article
CAS
PubMed
PubMed Central
Google Scholar
Deng L, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124(2):687–95.
Article
CAS
PubMed
PubMed Central
Google Scholar
Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7.
Article
CAS
PubMed
Google Scholar
Winograd R, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3(4):399–411.
Article
CAS
PubMed
PubMed Central
Google Scholar
Burrack AL, et al. Combination PD-1 and PD-L1 blockade promotes durable neoantigen-specific T cell-mediated immunity in pancreatic ductal adenocarcinoma. Cell Rep. 2019;28(8):2140-2155.e6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zheng NN, et al. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. World J Gastroenterol. 2020;26(26):3737–49.
Article
CAS
PubMed
PubMed Central
Google Scholar
O’Reilly EM, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5(10):1431–8.
Article
PubMed
PubMed Central
Google Scholar
Ghosh S, et al. TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo. Mol Cancer Ther. 2019;18(3):632–41.
Article
CAS
PubMed
Google Scholar
Burova E, et al. Preclinical development of the anti-LAG-3 antibody REGN3767: characterization and activity in combination with the anti-PD-1 antibody cemiplimab in human PD-1xLAG-3 -Knockin mice. Mol Cancer Ther. 2019;18(11):2051–62.
Article
CAS
PubMed
Google Scholar
Zhang D, et al. Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody. Oncoimmunology. 2020;9(1):1744921.
Article
PubMed
PubMed Central
Google Scholar
Saleh R, Toor SM, Elkord E. Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. Expert Opin Ther Targets. 2020;24(12):1251–62.
Article
CAS
PubMed
Google Scholar
Chauvin JM, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Investig. 2015;125(5):2046–58.
Article
PubMed
PubMed Central
Google Scholar
de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;38(3):326–33.
Article
PubMed
Google Scholar
Brower V. Hyperprogressive disease with anti-PD-1 and anti-PD-L1. Lancet Oncol. 2016;17(12):e527.
Article
PubMed
Google Scholar
Kanjanapan Y, et al. Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities. Cancer. 2019;125(8):1341–9.
Article
CAS
PubMed
Google Scholar